Novel therapeutic approach to melanoma-bearing hosts with protein-transduction technology
Project/Area Number |
20390306
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Dermatology
|
Research Institution | University of Yamanashi |
Principal Investigator |
SHIMADA Shinji University of Yamanashi, 大学院・医学工学総合研究部, 教授 (10114505)
|
Co-Investigator(Kenkyū-buntansha) |
SHIABAGKI Naotaka 山梨大学, 大学院・医学工学総合研究部, 准教授 (40262662)
KAWAMURA Tatsuyoshi 山梨大学, 医学部附属病院, 講師 (70262657)
HARADA Kazutoshi 山梨大学, 医学部附属病院, 講師 (20324197)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥18,850,000 (Direct Cost: ¥14,500,000、Indirect Cost: ¥4,350,000)
Fiscal Year 2010: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2009: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2008: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
|
Keywords | 悪性黒色腫 / 腫瘍ワクチン / 分子標的薬 / 分子標的療法 / 癌遺伝子 / ワクチン / 免疫療法 / 治療 / 免疫抑制 / 樹状細胞 |
Research Abstract |
Protein-transduction domains (PTDs) are short stretches of cationic amino acids that enable peptides, proteins, oligonucleotides, and other reagents to efficiently enter multiple cell types. Therefore, PTDs offer unique therapeutic opportunities for the treatment of many diseases, including malignant melanoma. Intratumoral injections of R9-antigens and R9-containing STAT3 inhibitors can reduce tumor growth in vivo.
|
Report
(4 results)
Research Products
(25 results)